antibody

Mouse Cdkn2a Antibody (Center)

MBS9204567

0.08 mL

165 USD

polyclonal

rabbit

nonconjugated

western blot, ELISA, enzyme immunoassay

Antibody

Mouse Cdkn2a Antibody (Center)

[Cdkn2a]

[Cyclin-dependent kinase inhibitor 2A; isoform 3; p19ARF; Cdkn2a {ECO:0000312 EMBL:AAB357701; ECO:0000312 MGI:MGI:104738}]

[cyclin-dependent kinase inhibitor 2A isoform 1; Tumor suppressor ARF; cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A; Alternative reading frame; ARF; Cyclin-dependent kinase inhibitor 2A; p19ARF]

[Cdkn2a]

[Cdkn2a; Cdkn2a; Arf; p16; MTS1; Pctr1; p19ARF; p16INK4a; p19 ARF ARF-INK4a; INK4a-ARF; Ink4a/Arf; p16(INK4a); ARF]

ARF_MOUSE

Polyclonal

Rabbit Ig

Rabbit

Mouse

[39-65]

168

This Mouse Cdkn2a antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 39-65 amino acids from the Central region of mouse Cdkn2a.

Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Vial Concentration: 0.5

Maintain refrigerated at 2-8 degree C for up to 2 weeks. For long term storage store at -20 degree C in small aliquots to prevent freeze-thaw cycles.

Western Blot (WB), ELISA (EIA)

WB~~1:1000

Western Blot (WB)

Antigen Type: Synthetic Peptide. Clone Names: RB40175

Antigen Source: MOUSE. Function: Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2- induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with COMMD1 and promotes its 'Lys63'-linked polyubiquitination (By similarity). Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development. Isoform smARF may be involved in regulation of autophagy and caspase-independent cell death; the short-lived mitochondrial isoform is stabilized by C1QBP. Cellular Location: Nucleus, nucleolus {ECO:0000250 UniProtKB:Q8N726, ECO:0000269 PubMed:10359817, ECO:0000269 PubMed:15567177, ECO:0000269 PubMed:15601844, ECO:0000269 PubMed:8521522}. Nucleus, nucleoplasm

Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development.

Nogueira, C., et al. Oncogene 29(47):6222-6232(2010). Fernandez-Diaz, L.C., et al. Development 137(20):3393-3403(2010). Bennecke, M., et al. Cancer Cell 18(2):135-146(2010). Negishi, M., et al. PLoS ONE 5 (8), E12373 (2010) :. Ulanet, D.B., et al. PLoS ONE 5 (8), E12454 (2010) :

6753390

NP_034007.1

NM_009877.2

Q64364

19238

p16-INK4A iso3: a cell-cycle regulatory protein that interacts with CDK4 and CDK6, inhibiting their ability to interact with cyclins D. Inhibits the phosphorylation of the retinoblastoma protein by CDK4 or CDK6, and entry into the S phase of the cell cycle. The p16INK4A and p14ARF proteins are encoded by CDKN2A, a known tumour suppressor gene in multiple cancers. CDKN2A is inactivated in 72% of cases of lung squamous cell carcinoma: 21% by epigenetic silencing by methylation, 18% inactivating mutation, 4% by exon 1b skipping, and 29% by homozygous deletion. Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome, Li-Fraumeni syndrome, and the melanoma-astrocytoma syndrome. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Four alternatively spliced p16 isoforms have been reported. Two alternatively spliced isoforms of ARF have been reported. Protein type: Cell cycle regulation; Tumor suppressor; Nucleolus. Cellular Component: nucleoplasm; nuclear body; granular component; protein complex; mitochondrion; cytoplasm; nucleolus; nucleus. Molecular Function: cyclin-dependent protein kinase inhibitor activity; NF-kappaB binding; protein binding; DNA binding; p53 binding; ubiquitin-protein ligase inhibitor activity; protein kinase binding; transcription factor binding; transcription factor activity. Biological Process: epidermis development; protein polyubiquitination; positive regulation of apoptosis; apoptosis; somatic stem cell maintenance; positive regulation of transcription, DNA-dependent; positive regulation of apoptosis involved in mammary gland involution; regulation of protein stability; negative regulation of B cell proliferation; glucose homeostasis; response to organic cyclic substance; negative regulation of cell cycle; regulation of protein export from nucleus; negative regulation of cell proliferation; apoptotic mitochondrial changes; regulation of transcription, DNA-dependent; regulation of G2/M transition of mitotic cell cycle; somatic stem cell division; cell cycle arrest; negative regulation of protein binding; aging; caspase activation; response to drug; negative regulation of immature T cell proliferation in the thymus; protein stabilization; transcription, DNA-dependent; protein destabilization; negative regulation of cyclin-dependent protein kinase activity; cell aging; negative regulation of cell-matrix adhesion; cell cycle; response to organic nitrogen; negative regulation of mammary gland epithelial cell proliferation; rRNA transcription; positive regulation of protein sumoylation; inhibition of NF-kappaB transcription factor; regulation of gene expression; regulation of nucleocytoplasmic transport; negative regulation of ubiquitin-protein ligase activity; negative regulation of phosphorylation; negative regulation of protein kinase activity; positive regulation of transcription factor activity; positive regulation of transcription from RNA polymerase II promoter; positive regulation of DNA damage response, signal transduction by p53 class mediator; negative regulation of cell growth; regulation of cyclin-dependent protein kinase activity; negative regulation of transcription, DNA-dependent; rRNA processing; G1/S transition of mitotic cell cycle

0.08 mL

165 USD

0.4 mL

370